ONCAlert | Upfront Therapy for mRCC
News
Robust Responses With ROCK2 Inhibition Are Seen in Chronic GVHD
8:30 PM, Mon February 24, 2020
Real-World Analysis Explores Current Role of Acalabrutinib in MCL
8:26 PM, Mon February 24, 2020
FDA Grants Priority Review to Brigatinib in ALK-Positive Metastatic NSCLC
4:49 PM, Mon February 24, 2020
Polatuzumab Vedotin Plus Bendamustine/Rituximab Shows Encouraging Activity in R/R DLBCL
2:20 PM, Mon February 24, 2020
Updated Results of CheckMate 025 Confirm Benefits of Nivolumab Over Everolimus in RCC
4:00 PM, Sun February 23, 2020
Genetic Profiling Suggests Rationale for Limited Response to Immunotherapy in Osteosarcoma
8:00 PM, Fri February 21, 2020
Novel Immunotherapy Agent ADXS-503 Plus Pembrolizumab Signals Promise in NSCLC
6:00 PM, Fri February 21, 2020
Conditioning Therapy With Iomab-B Improves Transplant Outcomes in Active AML
3:30 PM, Fri February 21, 2020
